%A Pan Xuefeng, Xing Hongyu, Zheng Guobao %T Bevacizumab for glioma and radiation encephalic necrosis %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.01.009 %P 27-30 %V 41 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9272.shtml} %8 2014-01-08 %X The U.S. Food and Drug Administration approves bevacizumab for salvage therapy of glioblastoma in 2009, which is the first monoclonal antibody of antiangiogenesis in the global. Afterwards, bevacizumab for malignant glioma becomes the focus of research, but the latest studies do not support its use for the firstline treatment of malignant glioma. Furthermore, bevacizumab shows a encouraging effect for radiation encephalic necrosis and its final outcome remains to be further confirmed.